Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells

2 Jul 2022

Abstract excerpt

Epigenetic modifications could drive some of the molecular events implicated in proliferation, drug resistance and metastasis of pancreatic ductal adenocarcinoma (PDAC). Thus, epigenetic enzyme inhibitors could be the key to revert those events and transform PDAC into a drug-sensitive tumor. We performed a systematic study with five different epigenetic enzyme inhibitors (1, UVI5008, MS275, psammaplin A, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35890123
DOI: 10.3390/ph15070824

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsPMID 35890123Read ↗

An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Epigenetic targeting in pancreatic cancerSemantic proximity Read ↗

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read ↗

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read ↗

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancerSemantic proximity Read ↗

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic CancerSemantic proximity Read ↗

Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic CancerSemantic proximity Read ↗

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.Semantic proximity Read ↗

DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implicationsSemantic proximity Read ↗

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read ↗

Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic CancerSemantic proximity Read ↗

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.